[Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure].
In 10 patients with chronic renal insufficiency we are tissue plasminogen activator antigen (t-PA Ag), tissue plasminogen activator inhibitor (PAI-1) and euglobulin lysis time (ELT) designed. This parameters are just before hemodialysis, in 60 minutes and 240 minutes after beginning of dialysis studied. In 60 minutes after the beginning of hemodialysis significant increased tissue plasminogen activator inhibitor antigen, decreased tissue plasminogen activator inhibitor activity and prolonged euglobulin lysis time. The observed increase in plasma t-PA antigen levels during hemodialysis is due to effects of extracorporal circulation on the fibrinolytic system. T-PA release and consequent consumption of tissue plasminogen activator inhibitor due to enhanced fibrinolytic activity during hemodialysis.
Piatkowska
M
M
Katedry i Zakładu Patofizjologii, Akademii Medycznej w Bydgoszczy.
Kotschy
M
M
Nartowicz
E
E
Rajewski
W
W
D000328:Adult; D000941:Antigens; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000627:therapeutic use*; D006435:Renal Dialysis; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D000941:Antigens; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D010959:Tissue Plasminogen Activator